Insulin glulizin
Prijeđi na navigaciju
Prijeđi na pretragu
| |
| Klinički podaci | |
|---|---|
| Robne marke | Apidra, Apidra SoloStar |
| AHFS/Drugs.com | glulisine.html Monografija |
| Identifikatori | |
| CAS broj | 207748-29-6 |
| ATC kod | A10AB06 |
| DrugBank | DB01309 |
| Hemijski podaci | |
| Formula | C258H384N64O78S6 |
| Mol. masa | 5823 |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | 42 minuta |
| Farmakoinformacioni podaci | |
| Trudnoća | ? |
| Pravni status | |
| Način primene | Subkutano |
Insulin glulizin je biosintetički, brzo delujući analog ljudskog insulina koji se proizvodi pomoću nepatogene laboratorijske bakterije Escherichia coli (K12). Ovaj rekombinantni hormon se razlikuje od prirodnog ljudskog insulina po tome što je aminokiselina arginin u poziciji B3 zamenjena lizinom i lizin u poziciji B29 je zamenjen glutaminskom kiselinom. Te strukturne modifikacije snižavaju stopu formiranja heksamera, stabilizuju insulin glulizinske monomere i povećavaju brzinu apsorpcije i početak dejstva u odnosu an ljudski insulin.[1][2][3][4][5][6][7][8][9][10][11]
Reference[uredi | uredi kod]
- ↑ Arnolds S, Rave K, Hovelmann U, Fischer A, Sert-Langeron C, Heise T: Insulin Glulisine Has a Faster Onset of Action Compared with Insulin Aspart in Healthy Volunteers. Exp Clin Endocrinol Diabetes. 2010 Apr 28. PMID 20429049
- ↑ Becker RH: Insulin glulisine complementing basal insulins: a review of structure and activity. Diabetes Technol Ther. 2007 Feb;9(1):109-21. PMID 17316105
- ↑ Becker RH, Frick AD: Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clin Pharmacokinet. 2008;47(1):7-20. PMID 18076215
- ↑ Cox SL: Insulin glulisine. Drugs Today (Barc). 2005 Jul;41(7):433-40. PMID 16193096
- ↑ Garnock-Jones KP, Plosker GL: Insulin glulisine: a review of its use in the management of diabetes mellitus. Drugs. 2009 May 29;69(8):1035-57. doi: 10.2165/00003495-200969080-00006. PMID 19496630
- ↑ Horvath K, Bock G, Regittnig W, Bodenlenz M, Wutte A, Plank J, Magnes C, Sinner F, Furst-Recktenwald S, Theobald K, Pieber TR: Insulin glulisine, insulin lispro and regular human insulin show comparable end-organ metabolic effects: an exploratory study. Diabetes Obes Metab. 2008 Jun;10(6):484-91. Epub 2007 Aug 30. PMID 17764465
- ↑ Insuline glusine (Apidra): a new rapid-acting insulin. Med Lett Drugs Ther. 2006 Apr 24;48(1233):33-4. PMID 16625142
- ↑ Robinson DM, Wellington K: Insulin glulisine. Drugs. 2006;66(6):861-9. PMID 16706558
- ↑ Ulrich H, Snyder B, Garg SK: Combining insulins for optimal blood glucose control in type I and 2 diabetes: focus on insulin glulisine. Vasc Health Risk Manag. 2007;3(3):245-54. PMID 17703632
- ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. DOI:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682.
- ↑ David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. DOI:10.1093/nar/gkm958. PMC 2238889. PMID 18048412.
Literatura[uredi | uredi kod]
- Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7.
- Thomas L. Lemke, David A. Williams, ur. (2007). Foye's Principles of Medicinal Chemistry (6 izd.). Baltimore: Lippincott Willams & Wilkins. ISBN 0-7817-6879-9.
